MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) today announced the signing of a research collaboration with New Zealand-based Genesis Research and Development Corporation Ltd. (New Zealand Stock Exchange: GEN).
Ventracor (ASX: VCR) today announced the 150th implant of the VentrAssist Left Ventricular Assist Device (LVAD).
Ventracor (ASX: VCR) today announced its results for the year ending 30 June 2007, with increasing sales revenues in the US, Europe and Australasia of $4.9m (2006;$1.1m) from 64 implants, and a net loss of $36.5m (2006;$30m).
Ventracor (ASX: VCR)(ADR: VTCRY) today announced the first patient implant in the US Bridge to Transplant (BTT) pivotal trial of the VentrAssist(tm) left ventricular assist device (LVAD) at the Medical University of Minnesota, in Minneapolis.
Ventracor (ASX: VCR)(ADR: VTCRY) yesterday confirmed growing momentum in Europe and the USA, with increases in the number of VentrAssist(tm) Left Ventricular Assist Device (LVAD) implants, resulting in record monthly sales revenue.
Ventracor (ASX: VCR) (ADR: VTCRY) is about to commence two major clinical trials in the US after the company successfully completed a Feasibility Trial. The first is a Bridge to Transplant (BTT) Pivotal Trial for patients on the transplant list; the FDA recently approved the start of this trial.
Mr William Curran, who joins the board effective immediately, is a New York-based company director with extensive experience in the medical device industry, including a 28-year career with Philips culminating in a senior role with Philips Medical Systems in USA.
